darbepoetin alfa (NuPIAO)
/ 3SBio
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
December 15, 2023
Canakinumab with darbepoetin in patients with lower-risk MDS who are ESA-refractory
(YouTube)
- "Jeffrey Lancet...discusses findings from a Phase I trial (NCT04798339) evaluating the combination of interleukin 1β (IL-1β) neutralizing antibody canakinumab with darbepoetin in the treatment of patients with lower-risk myelodysplastic syndromes (LR-MDS) who are refractory to erythropoietin stimulating agents (ESA). The combination inhibited inflammasome activation, hypothesized as a key driver of MDS pathogenesis, although this did not translate to clinical responses."
Interview • Video
May 04, 2016
3SBio: Annual Report 2015
(3SBio)
- Anticipated launch for anemia associated with CKD in 2020
Anticipated launch • Biosimilar
August 28, 2016
3SBio: Interim Results 2016 Investor Conference Call
(3SBio)
- Anticipated initiation of P2 trial in anemia associated with CKD in early 2017
Anticipated new P2 trial • Biosimilar
1 to 3
Of
3
Go to page
1